 pipelin move focu legaci busi slow initi
coverag neutral rate valuat rang
messag initi coverag neutral rate valuat rang global
diversifi compani guid revenu pipelin invest focus
cardiometabol inflamm cancer therapeut area success enbrel patent litig otezla acquisit celg/
announc key driver multipl expans rel biopharma peer believ stock
current fairli valu base growth profil think investor requir visibl addit sourc ebit growth
current consensu compound-annual-growth-rate time view addit downsid risk exist current street
consensu estim amgn portfolio mature-lifecycl legaci product face brand biosimilar competit think
current early- mid-lifecycl growth product alon may fulli off-set revenu eros declin legaci product
gener posit view amgn late-stag pipelin estim alreadi significantli consensu
valuat rang per share base multipl rang ebit estim
initi coverag neutral rate valuat rang global diversifi
market cap compani revenu guid product sale deriv wide rang
commerci asset span hematolog oncolog inflamm nephrolog cardiovascular bone health well pipelin
invest focus cardiometabol inflamm cancer therapeut area stock current trade ev/
ev/ebit well within standard deviat histor rang absolut basi though undergon signific
multipl expans rel biopharma peer follow success enbrel patent litig otezla acquisit
celg/bmi announc discount previous in-lin biopharma peer believ stock trade
level multipl expans would need support signific addit growth estim least
current consensu ebit compound-annual-growth-rate think could challeng base view addit
downsid risk street consensu estim amgn portfolio mature-lifecycl legaci product enbrel neulasta
epogen aranesp vectibix nplate sensipar may erod faster-than-expect street given increas innov
biosimilar competit unlik view amgn declin legaci busi fulli off-set growth current
market early-mid life-cycle product otezla repatha aimovig parsabiv prolia xgeva even kyproli blincyto imlyg
corlanor key new product launch repatha aimovig disappoint high-revenu product
otezla could potenti face competit risk long-term bmi gener posit view amgn late-
stage pipelin estim alreadi significantli consensu driven posit view biosimilar portfolio
kra inhibitor incorpor pos-adjust estim tezepelumab asthma omecaptiv heart failur well
earlier develop stage opportun
see addit downsid risk street consensu estim amgn mature-lifecycl legaci product current
estim compound-annual-growth-rate declin legaci segment rel consensu vs consensu
sale legaci asset includ anti-inflammatori biolog enbrel granulocyt colony-stimul factor g-csf neulasta
erythropoietin stimul agent esa aranesp epogen constitut legaci sale total
face increas competit headwind newer innov drug and/or biosimilar believ continu under-estim
street view faster-than-expect declin legaci busi driven primarili view g-csf esa eros
creat bluematrix
page analyst certif import disclosur
regard neulasta estim near-term yoy sale declin oppos consensu estim yoy follow
yoy subsequ year below-consensu g-csf estim base analysi overal biosimilar market
trend pl see page report line neulasta initi yoy declin post-biosimilar emerg
full year impact novn ziextenzo approv late annual yoy declin sinc biosimilar emerg
similarli believ epogen consensu bullish assum annual declin yoy eros model
despit competit altern erythropoietin stimul agent emerg biosimilar alreadi drove
yoy declin fy sale
think current early- mid-lifecycl growth product alon may fulli off-set revenu eros declin legaci
product current estim compound-annual-growth-rate growth segment rel consensu vs
consensu growth asset includ repatha cardiovascular anti-cgrp aimovig migrain calcimimet parsabiv
hyperparathyroid ckd prolia xgeva even osteoporosi proteasom inhibitor kyproli multipl myeloma bite product
blincyto asset oncolyt viru imlyg melanoma ion channel blocker corlanor heart failur
estim above-consensu sale growth certain key product prolia driven primarili continu increas new patient
start refil rate partial penetr market without same-class competitor see page overal growth segment
estim street incorpor potenti downsid risk key product otezla current reflect
long-term consensu estim potenti competit inhibitor base bmi upcom head-to-head trial result
see page commerci launch key growth product aimovig repatha disappoint
undertaken step improv access afford repatha go full effect calendar year remain conserv
forecast sale in-lin consensu given limit visibl net price stabil longer term without transpar potenti
impact decreas patient abandon medicar channel see page similarli chronic migrain market continu
grow slow rate competit aimovig cgrp market intensifi potenti pressur net sell
price see page denosumab franchis prolia xgeva one strongest asset
conserv view market potenti even follow interview kol highlight rel lower number treatment
candid anabol agent potenti safeti concern black box warn see page
gener posit view amgn late-stag pipelin estim alreadi significantli
consensu current forecast pos-adjust pipelin revenu rel consensu base prior
extens work kra opportun competit landscap takeaway oncolog day kol panel
nsclc kol takeaway kra bullish potenti wholly-own first-in-class kra inhibitor
may address annual revenu opportun lung colorect pancreat cancer view see page
addit recent complet enrol registration-direct single-arm phase ii monotherapi studi lung cancer data
compani confirm plan confirmatori phase trial lung cancer random docetaxel pursu wide array
combin studi inhibitor target see initi mek rog-sw cotel
keytruda pan-erbb inhibitor given first-mov advantag field combin may ultim dictat util
see kol feedback clinical-stag asset believ captur peak market
share pos-adjust revenu vs consensu also posit biosimilar portfolio see
page compani well-posit portfolio biosimilar innov brand gener
sale street expect continu increas year ago success think omecamtiv could potenti achiev
peak sale base case scenario heart failur market among patient reduc eject fraction therapeut area
high unmet medic need surviv rate par observ lung cancer see page promis ph
ii data demonstr increas cardiac function well decreas cardiac risk ii ph galactic-hf trial proceed
interim analys per data monitor committe recommend bode well omecamtiv potenti justifi po
assumpt head pivot data year-end view market posit vs azn farxiga key factor
line consensu tezepelumab see page offer differenti mechan action asthma biolog
type patient success may captur share non-typ asthma current biolog penetr
consensu bispecif t-cell engag bite platform see page given potenti competitor headwind next-gener
 bispecif antibodi platform see coverag initi transfer
page analyst certif import disclosur
valuat rang per share estim potenti base case hypothet bull
bear case scenario year share current trade non-gaap ebit consensu estim essenti in-lin
larg cap biopharma peer group averag think consist growth profil see page current
estim top ebit bottom line compound-annual-growth-rate respect valuat rage base
multipl ebit estim base sum-of-part dcf valuat analysi take account asset durat
ip runway attribut valuat legaci busi growth portfolio pipelin includ
biosimilar busi swing factor base case valuat includ pace declin legaci busi
bull/bear case scenario primarili g-csf epo franchis well enbrel growth/competit key growth product
includ otezla aimovig repatha bull/bear case scenario amgn pipelin deliv fail
swing factor latter includ potenti success disappoint key pipelin product includ biosimilar bite
asset beyond blincyto tezepelumab omecamtiv combin see valuat bookend year indic
think balanc risk/reward current valuat
page analyst certif import disclosur
initi coverag
page analyst certif import disclosur
tabl content
page analyst certif import disclosur
page analyst certif import disclosur
initi coverag neutral rate
trade within histor multipl rang rel valuat vs large-cap biopharma peer
indic signific multipl expans account macro factor
current trade ev/ ev/ebit well within standard deviat histor rang
account macro factor amgn rel valuat indic signific multipl expans vs peer
enbrel ip litig win otezla acquisit key driver amgn near-term growth outlook rais street
expect impli ebit compound-annual-growth-rate
believ stock trade level multipl expans would need support signific addit
growth estim least think could challeng without addl accret
see addit downsid risk street consensu estim amgn mature-lifecycl legaci
current estim compound-annual-growth-rate declin legaci segment rel consensu vs
consensu sale
think current early- mid-lifecycl growth product alon may fulli off-set revenu eros
current estim compound-annual-growth-rate growth segment rel consensu vs
consensu
gener posit view amgn late-stag pipelin estim alreadi
significantli consensu
current forecast pos-adjust pipelin revenu rel consensu
page analyst certif import disclosur
current fair valu estim consist revenue-gener legaci
growth product along advanc clinical-stag asset
valuat breakdown segment
net invest lt debt
rel consensu estim
epogen on-going sale declin epogen aranesp
neulasta consensu long-act g-csf expect
continu underestim biosimilar eros neulasta may track
similar neupogen sale eros upon biosimilar entri
valuat breakdown product
net invest lt debt
aimovig consensu intensifi competit broader cgrp
landscap multipl rel undifferenti product
even consensu uphil battl black box warn
cardiovascular risk competit gener forteo
sustain potenti competit risk inhibitor
includ commerci product imlyg corlanor
nplate bite platform blincyto oncolog pipelin agent
inflamm pipelin sensipar
prolia consensu continu increas revenu market share
absenc same-class competitor
consensu still underappreci street given
remain clinic risk first-mov advantag potenti bn ww
biosimilar consensu well-posit broad
biosimilar portfolio target high-opportun innov product
increasingli biosimilar-friendli landscap us
page analyst certif import disclosur
trade upper end histor multipl rang
ev/ within histor rang
ev/ebit within histor rang
ev/ within histor rang
ev/ebit within histor rang
page analyst certif import disclosur
account macro factor amgn rel valuat indic
multipl expans vs peer
ev/ebit vs peer
amgn multipl expand rel peer
trade in-lin biopharma peer vs histor discount
page analyst certif import disclosur
enbrel patent case win otezla acquisit key driver
amgn near-term growth outlook
signific increas amgn growth expect consensu ebit enbrel patent upheld
follow acquisit otezla
share price consensu growth rate
page analyst certif import disclosur
trade line peer think addl increas ebit
compound-annual-growth-rate would necessari justifi ev/ebit multipl expans
page analyst certif import disclosur
slightli conserv view amgn organ growth
slightli street ebit forecast
slightli street dilut ep forecast
page analyst certif import disclosur
potenti addit capac compani
histor disciplin
otezla bmy/celg
cardiovascular portfolio dyslipidemia
kyproli asset bayri
page analyst certif import disclosur
like moder impact global pandem point
pose potenti downsid risk market disrupt prolong month
statu late-march pandem
mid-march made decis everyon organ begin work home
part busi continu plan manag confirm futur impact rule
depend durat pandem believ manag gener market
disrupt limit month
manag confirm make decis relat clinic trial study-by-studi basi
anticip disrupt impact earlier stage studi vs near completion/ fulli
enrol fulli enrol pivot ph program omecamtiv mecarbil tezepelumab well
pivot ph ii studi kras-inhibitor accumul follow-up data point remain
larg track
impact therapeut area lower urgency/ delay treatment studi yet
start and/or yet complet enrol
least impact therapeut area higher urgency/in delay treatment studi
sale rep field staff work home advis fulli adapt virtual
interact model manag note time like patient may tendenc stock-pile/
hoard medic could potenti dull rx trend patient begin stay home avoid trip
pharmaci
impact non-crit hc provider-administ product prolia even new
launch affect lack in-person sale promot aimovig
least impact product high medic need therapeut area oncolog nephrolog
well-establish brand consum base experienc fill renew prescript enbrel
confirm like biotech compani tend keep suffici inventori hand suppli
market without interrupt
sale hc-provid administ drug non life-threaten condit new launch
risk longer term view prolia even aimovig
page analyst certif import disclosur
classifi amgn product legaci growth pipelin asset
matur life-cycle drug either current could potenti near-
term face loss exclus gener biosimilar
early-to-mid life-cycle drug expect contribut top-line revenu
growth near-to-medium term
otezla small molecul anti-inflammatori drug current approv
psoriat arthriti psoriasi oral ulcer associ behcet
diseas drug acquir celg post-bmi acquisit
biosimilar biolog drug pursu indic loss
exclus innov molecul open new opportun
advanc clinical-stag drug provid line-of-
sight potenti develop path market oppti etc
page analyst certif import disclosur
consensu legaci growth asset
consensu biosimilar innov clinical-stag pipelin
current forecast top-line revenu compound-annual-growth-rate level
street consensu forecast slightli aggress top-line revenu compound-annual-growth-rate level
guggenheim secur llc analysi visibl alpha consensu pipelin product includ bite oncolog cardiovascular pipelin asset growth product includ parsabiv prolia xgeva even kyproli blincyto
repatha aimovig other imlyg corlanor etc legaci asset includ neulasta aranesp epogen enbrel sensipar nplate vectibix
page analyst certif import disclosur
think street continu underestim declin sale legaci
product particular g-csf esa
legaci product street consensu high view
particularli exclud recent enbrel ip win
street expect g-csf esa sale legaci revenu histor high
page analyst certif import disclosur
consensu revenu estim commercial-stag growth
product think may insuffici off-set legaci asset declin
growth asset wont off-set legaci declin view
consensu growth asset
street significantli overestim potenti key growth product repatha aimovig
blincyto repatha aimovig other imlyg corlanor etc
page analyst certif import disclosur
consensu otezla account potenti competit
risk inhibitor base case scenario
think otezla sale could act short-term bridg
consensu estim modest overal growth otezla
bmi inhibitor may repres long-term competit given strong phase ii data phase random vs otezla
spg score
end intervent period
end intervent period
week
spg
blincyto repatha aimovig other imlyg corlanor etc
page analyst certif import disclosur
recent increas focu innov pipelin focus
hematology/oncolog inflamm cardiovascular therapeut area
 spend pipelin recent increas
focu area clinic develop
 spend non-commerci asset
provid data updat
phase asthma studi read
readout ye
three core area effort per management
roll back neurosci discoveri effort
page analyst certif import disclosur
consider consensu given first-mov
advantag pursu annual overal ww opportun
consider consensu
biomarker-direct therapi potenti similar patient opportun gener annual multi-billion dollar sale
page analyst certif import disclosur
larg line street consensu key pipelin
opportun tezepelumab asthma omecamtiv heart failur
tezepelumab headwind type asthma competitor biolog new mechan open potl oppti beyond type
slightli consensu long-term larg market opportun moder competit headwind develop risk
page analyst certif import disclosur
biosimilar also key growth opportun view
well-posit street expect continu rise
slightli consensu expect risen
recent launch captur share year
first biosimilar launch best commerci execut
launch
share year
mvasi share far
 post-launch
strong us launch amgn oncolog biosimilar
near-term biolog loe open addl oppti biosimilar
partial data given data yet fulli account also
disclos exit share come us
captur ia data trastuzumab biosimilar
potl loss
management highlight
biosimilar innov gener
ww product sale
page analyst certif import disclosur
in-lin biopharma peer consist
growth profil slide
upsid risk higher sale earn growth rate expect
pipelin success beyond account forecast
downsid risk regulatori setback lower sale earn
growth rate expect potenti impact
legaci product continu erod line
recent histor trend emerg biosimilar
growth product continu sale ramp-up
begin face competit near-term
success key pipelin product
legaci product declin slower expect
strong sale ramp-up growth product
legaci product declin faster expect
page analyst certif import disclosur
see multipl potenti swing factor across portfolio
could impact long-term revenu forecast
high potenti impact swing factor long-term
sale eros high-impact legaci product g-csf
epo franchis well enbrel
uptak key growth product aimovig repatha
otezla opportun without competit
potenti success disappoint key pipelin product
omecamtiv
enbrel yoy sale eros increas
g-csf franchis neulasta continu erod yoy line
recent sale trend analog histor sale
epo franchis epogen yoy eros biosimilar increas
uptak aranesp yoy eros loe thereaft
aimovig migrain patient get cgrp market share
repatha strong double-digit growth
otezla double-digit growth via expans mild-moder
psoriasi deceler growth potenti competit
pipelin deliv first-mov long treatment
durat bite platform deliv tezepelumab penetr type
enbrel yoy sale eros increas
enbrel yoy sale eros
g-csf franchis faster neulasta eros yoy line
g-csf franchis slower neulasta eros yoy in-
line jnj remicad defens biosimilar
epo franchis epogen yoy eros biosimilar increas
uptak aranesp yoy eros loe thereaft
epo franchis epogen yoy eros biosimilar increas
uptak aranesp yoy eros loe thereaft
aimovig migrain patient get cgrp market share
aimovig migrain patient get cgrp market share
repatha double-digit growth minim thereaft
repatha strong double-digit growth
otezla modest uptak mild-moder psoriasi
displac otezla pre-biolog option moderate-sever set
otezla strong posit mild-moder psoriasi modest
competit impact moderate-sever set
pipelin competit headwind shorten treatment
durat bite insuffici differenti competit class
headwind teze type asthma valu indic
pipelin take major share first-mov longer
treatment durat strong bite readout multipl myeloma solid
page analyst certif import disclosur
revenu base bull bear case scenario vs street
overal base case slightli street consensu
consensu optimist legaci eros view
think consensu optimist growth segment
pipelin highli underappreci street view
page analyst certif import disclosur
valuat base bull bear case scenario product segment
overal base bull bear case valuat
legaci segment scenario valuat
growth segment scenario valuat
pipelin scenario valuat
page analyst certif import disclosur
page analyst certif import disclosur
clinicalproductindicationtrialpotenti catalysttimingotezlamild-to-moder psoriasisph advanceful psoriasisph sproutful psoriasisph discreetful uncontrol asthmaph navig sourc path-homeful dataend uncontrol asthmaph destinationsafeti dermat moderate-to-sever ph ilbiniti obstruct pulmonari diseaseph iia courseiniti monotherapyph ii potenti pivot initi solid tumor type monotherapyph iiniti combo w/ keytrudaph iiniti bcma bite hle multipl myeloma r/rph iiniti myeloma r/r w/ rdph krd full myeloma r/r w/ idph ii ikema ikd full combo w/ keytrudaph non-hodgkin lymphomaph ii/initi transformationph nitial allph ii iit ibrutinibiniti bite hle dlbcl mcl flph iiniti plaquesph huygensful fourier oleful mecarbilheart failur reduc eject fractionph galactic-hfful data mecarbilheart failur reduc eject fractionph meteoric-hfful eculizumab biosimilar pnhph dahliaful high fractur riskpostmarket studysafeti filingtimingotezlascalp psoriasisph stylepdufa dateapril rituximab biosimilar non-hodgkin lymphomaph jasminepdufa dateoct myeloma r/r w/ ddph manag overview
chairman sinc ceo sinc previous cfo vice-president oper
manag director european bank corpor financ prior join
also member board director ba member board truste univers southern california
execut vice-president cfo sinc januari serv execut vice-president financ
formerli presid sherwood canyon group privat equiti firm ernst young
execut vice-president global commerci oper sinc
previous chief commerci offic well presid us oper
previous svp medic affair takeda well leadership posit clinic develop
prior role includ senior vice-president translat scienc oncolog
previous director clinic research breast cancer intern research group co-found presid
translat oncolog research intern
page analyst certif import disclosur
page analyst certif import disclosur
amgn legaci busi consist matur life-cycle drug
g-csf rapid eros due multipl biosimilar
gener consider revenu face on-going
near-term loss exclus subsequ competit
gener biosimilar
neulasta esa franchis epogen aranesp enbrel
sensipar vectibix nplate
legaci busi segment gener bn
revenu investor expect declin g-csf
 epogen biosimilar well sensipar gener captur
think legaci busi revenu declin
compound-annual-growth-rate compar consensu
estim declin compound-annual-growth-rate time period
esa moder eros epogen biosimilar
enbrel modest demand eros competitor new
differenti mechan action enter market
sensipar minim overal impact due gener entri
vectibix modest demand eros despit near-term lack
biosimilar newer drug enter market
nplate matur life-cycle product near-term composit
matter expir competit novn promacta
rate patient demand share and/or unit price
eros innov biosimilar competitor enter
market high-revenu enbrel neulasta aranesp
page analyst certif import disclosur
gsr estim
contribut
long-act version neulasta
approv chemotherapy- radiation-induc neutropenia
g-csf post-exclus declin revenu peak
neulasta
consensu compound-annual-growth-rate
g-csf product multipl biosimilar competitor
line neupogen consensu neulasta consensu
believ neulasta may erod compound-annual-growth-rate first year
post-biosimilar entri line eros zarxio
upsid g-csf revenu erod slower-than-expect pace
and/or eventu stabil higher level post loss-of-exclus
downsid g-csf revenu erod faster-than-expect pace
and/or eventu stabil lower level post loss-of-exclus
page analyst certif import disclosur
line neulasta street consensu
estim line consensu see taper sale eros
neulasta estim consensu estim yoy near-term eros vs assumpt
page analyst certif import disclosur
sale histor erod yoy upon biosimilar launch
page analyst certif import disclosur
given post-lo innov price trend consensu
think estim neulasta maintain share
pdufa
date pfe biosimilar
high-level methodolog normal forecast
estim unit price eros given year divid
sale estim impli neulasta share vs biosimilar
page analyst certif import disclosur
increasingli competit g-csf market
increas uptak pegfilgrastim biosimilar
continu neulasta revenu share unit price
eros line neupogen perform
abl defend market share similar jnj
remicad revenu stabil
revenu stabil longer term
revenu stabil longer term
neulasta erod yoy short term
neulasta erod yoy biosimilar
neulasta erod yoy short term
line remicad perform post-biosimilar
rolonti launch take share
line neupogen perform post-biosimilar
page analyst certif import disclosur
gsr estim
contribut
product erythropoiesis-stimul agent esa
approv treatment anemia due chronic kidney
diseas ckd myelosuppress chemotherapi
epogen aranesp revenu peak
respect modest annual declin thereaft
epogen biosimilar retacrit fda-approv
slightli street consensu
think epogen erod yoy given biosimilar competit
yoy perform aranesp moder declin
given recent trend potenti loss exclus
and/or unit sale better expect
downsid scenario erythropoietin stimul erod share
unit price faster expect competitor
page analyst certif import disclosur
higher-than-expect eros epogen sale due
biosimilar competit aranesp continu
declin us well row
continu eros epogen sale due biosimilar
competit well aranesp modest eros
row aranesp sale line sale
aranesp erod slower-than-expect us
row sale remain flat loe
epogen yoy eros
aranesp yoy eros us loe
epogen yoy eros
aranesp yoy eros us potl
epogen yoy eros
aranesp yoy eros us
yoy thereaft
aranesp row eros
aranesp row eros
page analyst certif import disclosur
gsr estim
contribut
approv rheumatoid arthriti ra psoriat arthriti
jia plaqu psoriasi pso
line street consensu
ip win novn potenti extend exclus expect
modest patient demand eros meantim given
compound-annual-growth-rate ww revenu iqvia
bull case scenario enbrel revenu remain flat modestli declin
us loss exclus
bear case scenario lower enbrel product sale forecast and/or
ip loss samsung bioepi biosimilar epicovo
appeal loss novn erelzi
page analyst certif import disclosur
anti-inflamm landscap becom increasingli crowd new
mechan beyond tnf blockad may erod enbrel demand
list approv anti-inflammatori agent
us entri humira biosimilar may
enbrel begin
page analyst certif import disclosur
enbrel estim larg line consensu assum
moder near-term sale eros loss exclus
enbrel iqvia declin compound-annual-growth-rate sinc
steadi unit price given compound-annual-growth-rate us sale
see modest eros increas time emerg competit new innov humira biosimilar
page analyst certif import disclosur
faster-than-expect enbrel sale eros
combin increas unit price eros
enbrel sale continu near-term eros
modestli acceler newer agent launch
near-term follow humira biosimilar
enbrel maintain unit price undergo
yoy eros modestli increas
yoy eros base recent sale
yoy upon entri humira biosimilar
trend assumpt continu declin
modest yoy net price declin
yoy eros start entri
yoy eros base recent trend
assumpt declin unit price
page analyst certif import disclosur
gsr estim
contribut
calcimimet via activ calcium-sens receptor
approv hyperparathyroid patient chronic
kidney diseas hemodialysi parathyroid carcinoma
revenu declin peak ww follow expiri
composit matter at-risk gener entri cannib
amgn parsabiv approv
given potenti convers patient next-gener calcimimet
parsabiv recent loss exclus multipl gener see
rapid near-term sale eros consensu
expir initi rule gener non-infring
page analyst certif import disclosur
gsr estim
contribut
approv metastat colorect cancer without ra
mutat combin chemotherapi
annual ww revenu impend loss exclus
near-term biosimilar competit
compet erbitux lly/mkkgi ra wild-typ indic
consensu although vectibix unlik face near-term
biosimilar remain standard-of-car agent ras-wild-typ
believ sale eros driven newer regimen
occupi biomarker-defin popul ra wild-typ
vectibix loss exclus
upsid near-term flat modestly-grow vectibix revenu
downsid rapid revenu eros potenti due emerg
newer biomarker-direct therapi biosimilar
ii data
phase data solid tumor
page analyst certif import disclosur
expect vectibix maintain revenu near term given patient
demand moder grow
ww sale iqvia us vectibix
quarter year
page analyst certif import disclosur
egfr mab remain standard-of-car raswt emerg
newer biomark therapi may erod vectibix share longer term
approv emerg biomarker-direct therapi ra wild type
ra wild-typ
keytruda opdivo
braf top-line
approv braf
enhertu phase ii data
tucatinib phase ii data
page analyst certif import disclosur
moderate-to-rapid eros patient demand
ras-wild type due emerg newer
agent well potenti new biosimilar
vectibix remain standard-of-car ras-wild type
undergo modest-moder eros
longer term potenti due emerg newer
agent biomark
vectibix remain standard-of-car ras-wild type
revenues/pati demand remain larg
flat near-term revenu follow moderate-
modest growth follow flat modest-
modest growth follow flat modestli
to-moder yoy declin annual
page analyst certif import disclosur
gsr estim
contribut
nplate romiplostim fusion protein analog thrombopoietin
increas platelet count agon thrombopoietin receptor
nplate approv adult pediatr chronic immun
thrombocytopenia itp insuffici respons
corticosteroid immunoglobulin splenectomi
growth driver label expans includ launch pediatr
patient year age itp approv adult itp
patient insuffici respons first-lin therapi earlier
nplate revenu forecast slightli street consensu
assum growth us com patent expir
model eros rate patent expir
upsid scenario higher-than-expect adopt earlier line itp
downsid scenario higher price reduct faster eros
expir patent eu
page analyst certif import disclosur
page analyst certif import disclosur
amgn growth busi consist early-to-mid life-cycle
drug continu grow near term
without same-class competitor uphil battl even
black box cv risk gener forteo competit
specif growth product includ bone franchis prolia
xgeva even otezla kyproli nplate blincyto
commerci asset corlanor imlyg
growth segment gener bn revenu
driven primarili bone franchis prolia xgeva
even kyproli sale
otezla high-revenu product payer access gross-to-
net price dynam potenti competit
kyproli continu growth multipl myeloma
blincyto compet primarili car-t half-lif
think growth asset revenu increas compound-annual-growth-rate
compar consensu estim
compound-annual-growth-rate growth time period
potenti clinical/commerci success key competitor
page analyst certif import disclosur
gsr estim
contribut
prolia denosumab mab target rnakl pathway inhibit
osteoclast-medi bone resorpt increas bone strength
prolia approv patient high risk fractur
osteoporosi glucocorticoid-induc osteoporosi
receiv non-metastat prostat cancer receiv
adjuv aromatas inhibitor therapi breast cancer
prolia approv rankl inhibitor indic osteoporosi
compar anabol promot bone format agent
forteo tymlo amgn even
approv indic prolia uniqu moa
favor safeti profil accord kol spoke
prolia ww revenu forecast higher consensu base
analysi prescript
believ prolia continu grow driven new start refil
patient osteoporosi high risk fractur
front-lin treatment patent expir us eu
upsid scenario growth post-even mainten treatment
downsid scenario loss market share due competit new
page analyst certif import disclosur
gsr estim
contribut
xgeva denosumab monoclon antibodi prolia
approv set differ indic base moa
xgeva approv prevent skeletal-rel event
multipl myeloma patient solid tumor patient bone metastas
patient giant cell tumor bone refractori
hypercalcemia malign
prolia xgeva approv rankl inhibitor indic
osteoporosi
rankl-target therapeut develop includ
nanobodi earli stage xgeva/prolia biosimiliar
xgeva ww revenu forecast larg line consensu
believ xgeva growth would primarili driven continu
adopt mm us near term approv rel
recent jan growth china current model
sale peak us
upsid scenario higher expect sale china
downsid scenario lower expect growth recent approv
page analyst certif import disclosur
gsr estim
contribut
even romosozumab monoclon antibodi target sclerostin
promot bone format anabol agent
even approv treatment osteoporosi postmenopaus
women high risk fractur
three anabol agent approv far reduc
even favor dose schedul black box
warn cv risk could concern accord kol spoke
anabol agent forteo tymlo
prarthyroid hormon analog prarthyroid hormon relat peptid
even revenu forecast slightli street consensu
assum osteoporosi patient high risk fractur us
even achiev peak share within patient popul
upsid scenario indic expans includ exampl male
osteoporosi patient glucocorticoid-induc osteoporosi pt
potenti approv eu posit result post-market studi
downsid scenario higher expect competit gener
forteo slow growth lower expect peak market share due
black box warn cv risk
post-market
page analyst certif import disclosur
market opportun anabol drug
us preval women
year osteoporosi
candid osteoporosi
base analysi script prolia current adopt high-risk
osteoporosi patient candid drug treatment
current model peak market penetr even
page analyst certif import disclosur
new anabol drug captur market share market
leader recent lost patent exclus
quarterli sale approv anabol agent
us market share approv anabol agent
market share calcul im eutrx data normal volum
driven ex-u sale
page analyst certif import disclosur
kol want see data justifi risk/reward even
kol view osteoporosi drug
kol like prolia cite sustain clinic benefit back long-term follow-up clinic studi demonstr
continu improv bone miner densiti bmd besid risk side-effect didnt seem increas follow-up
year kol believ prolia use drug osteoporosi patient
kol spoke prescrib anabol agent osteoporosi patient includ
treatment high dose glucocorticoid transplant medicin patient lose bone specif due lack
among three anabol agent one kol prefer forteo note drug market long time
comfort kol view forteo tymlo similar differ point tymlo
like get approv payer given slightli lower price
kol express concern black box warn cv risk associ even accord one kol
wnt signal pathway even target play central regulatori role across divers rang function
mechan cardiovascular side-effect yet fulli elucid kol want see data feel
comfort prescrib drug one kol yet prescrib even patient wherea
prescrib one patient
page analyst certif import disclosur
gsr estim
contribut
approv activ psoriat arthriti adult ii moder
sever plaqu psoriasi candid phototherapi
system therapi iii oral ulcer associ behcet diseas
otezla posit post-top pre-biolog option within
treatment paradigm still face overlap class
past otezla payer access issu higher
expect caus revenu fluctuat previou owner
model double-digit growth driven expans
mild-to-moder psoriasi ex-u deceler growth
otezla face increas competit bmi
moder psoriasi abl stave competit threat
downsid scenario minim mild-to-moder psoriasi uptak
bmi displac otezla pre-biolog option moderate-to-
page analyst certif import disclosur
despit rocki quarter otezla volatil appear temper
recent quarter strong qoq growth demonstr
fluctuat impli net price otezla temper last year overal net price
stay larg flat sinc initi launch despit larg fluctuat
otezla acquisit give access post-dmard pre-biolog market within psoriasi
psoriat arthriti strengthen posit within broader autoimmun class
increas frequenc malign
requir monitor
tabl adapt celg compani present
given rel safeti advantag otezla
combin wac launch
discount establish biolog product otezla
abl find less competit yet highli lucr nich
post-nsaid pre-biolog option psoriasi
patient initi otezla therapi biologic-
nave start treatment
page analyst certif import disclosur
addit label extens ex-u buildout could support near-
term growth view despit like continu commerci pressur
otezla could expand mild-to-moder
psoriasi pend ph data later year
also plan expand otezla global
footprint alreadi approv indic
acquisit otezla approv
countri launch manag
approv grant local regul
celg yet launch otezla reiter
execut global expans fit broader
corpor strategi grow intern footprint
diagnos patient psoriasi sever
determin base proport total bodi surfac
area bsa affect diseas gener mild defin
bsa moder defin bsa
sever defin moder popul
alreadi prescrib otezla per exist fda-approv
label upcom ph advanc trial could expand
otezla footprint across sever classif
channel check suggest physician alreadi use
otezla mild-to-moder patient given fda-
approv label alreadi includ moder patient
popul physician said rel easi time
reclassifi mild patient moder justifi fact
addit treatment warrant patient like
diseas increas sever alreadi
prescrib suggest us otezla address
mild popul may slightli smaller preval
page analyst certif import disclosur
howev bmi could potenti pose competit threat otezla
growth given strong efficaci profil on-going head-to-head trial
bmi show substanti increas efficaci ph ii trial rel otezla ph trial
like pose competit threat otezla growth within lucr psoriasi indic current run two ph
trial poetyk head-to-head versu otezla track read potenti launch set
physician spoke said could overtak otezla post-dmard pre-biolog product choic given
substanti higher efficaci compar market lead biolog
spg score
end intervent period
end intervent period
page analyst certif import disclosur
extent compet otezla depend primarili
safeti profil demonstr pivot trial
physician spoke look safeti profil determin whether
effect outcompet otezla moderate-to-sever psoriasi set howev price also key
per channel check clear us otezla clean safeti profil main compon physician-prescrib behavior
although otezla efficaci market-lead biolog found lucr nich post-dmard pre-biolog given
compar safer clinic profil well substanti discount price although physician spoke note
seen higher rate gastrointestin advers event otezla describ clinic trial gener consensu
otezla offer safe compel option patient moderate-to-sever psoriasi
although safeti profil clean ph ii
physician want data given target physician
spoke seem impress cleanli bmy-
safeti profil given high level activ howev
given close relationship jak-
famili appear hesit character
safe otezla point absenc
larger safeti databas gener ph trial
advers event seen ph ii gotten
attent pruritu itch upper respiratori tract
infect former major concern per
channel check latter seem shrug
given lack dose-depend relationship
said physician larg acknowledg prescrib behavior also dictat payer control patient
access physician spoke describ exist strong access otezla within psoriasi treatment paradigm
posit studi result would compel chang prescrib behavior physician spoke acknowledg
bmi rel price contract also play vital role adopt
page analyst certif import disclosur
bmi succe pivot head-to-head
trial vs otezla begin shrink otezla
opportun nich market moderate-to-
continu low double-digit growth
driven addit label extens includ mild-
to-moder psoriasi deceler
growth driven primarili increas competit
bmi moderate-to-sever psoriasi
bmi either fail show superior
otezla yield advers event
compar sever biolog otezla
continu grow nich pre-biolog market
 ex-u
caus yoy share eros
caus otezla share eros
psoriasi first full year post- launch follow
eros thereaft
moderate-sever psoriasi market
expans ex-u buildout off-set
otezla achiev doubl digit growth
follow low-to-mid singl digit growth
loss patent exclus
page analyst certif import disclosur
